October 14, 2026
The Science Behind Optogenetics
Nanoscope Therapeutics cofounder Samarendra Mohanty, PhD, discusses the development of MCO-010, the challenges of engineering light sensitivity, and unexpected findings from clinical trials.
2026 AAO Meeting
Related Content
October 14, 2026
Assessing PRIMA’s Efficacy and Safety at 36 Months
Long-term results from the PRIMAvera study show approximately 30 letters of mean visual acuity improvement at 36 months, with most serious adverse events occurring early after surgery.
October 13, 2026
Oculis CEO Outlines Phase 3 PIONEER Program
Riad Sherif, MD, discusses the development of privosegtor for optic neuritis and nonarteritic anterior ischemic optic neuropathy.
October 13, 2026
Behind the Scenes of Trials InSight
Drs. Minaker and Sambhara discuss the motivation behind their upcoming virtual meeting and its emphasis on collaboration across clinical research.
October 13, 2026
The Challenges of Bringing Retinal Therapies to Market
At Eyecelerator 2026 in New Orleans, industry leaders discussed the clinical, regulatory, and commercial considerations shaping the next generation of retinal treatments.
October 12, 2026
Topcon Launches Oku Digital Health at AAO
Daniela Ferrara, MD, PhD, discusses Topcon's new oculomics initiative and the potential of retinal imaging to help identify systemic diseases.
October 12, 2026
AAVantgarde Presents New Usher Syndrome Gene Therapy Data
Updated results from the LUCE-1 trial show no serious adverse events or dose-limiting toxicities, with early signals of improved visual acuity.
October 12, 2026
Three-Year MCO-010 Outcomes From RESTORE
Long-term findings presented in New Orleans suggest sustained visual function improvements in patients with advanced retinitis pigmentosa.
October 11, 2026
FDA Accepts Vamikibart BLA for Uveitic Macular Edema
New phase 3 data presented at AAO 2026 showed sustained visual and anatomic improvements through 52 weeks in the MEERKAT and SANDCAT trials.
October 11, 2026
Remigromig Meets Primary Endpoint in BRUNELLO Trial
Both doses of the Wnt pathway agonist met the primary noninferiority endpoint in evaluation against ranibizumab in patients with DME, Donald J. D’Amico, MD, reported at AAO.
October 10, 2026
Two-Year PRISM Data Show Reduced Treatment Burden
Veeral Sheth, MD, discusses the durability, safety, and supplemental injection requirements of intravitreal 4D-150 gene therapy for wet AMD.
October 10, 2026
Early ELAAVATE Data Show Promise in DME
Arshad M. Khanani, MD, FASRS, discusses preliminary safety and efficacy findings from a phase 2 study of subretinal sura-vec gene therapy.
October 10, 2026
Tarcocimab and Tabirafusp Meet Phase 3 Endpoints
At AAO 2026, Charles C. Wykoff, MD, PhD, presented positive DAYBREAK results for both Kodiak Sciences agents. A BLA submission for tarcocimab is planned later this year.
October 10, 2026
K8 Shows Greater GA Growth Reduction Over Time
Liangbo Shen, MD, reported additional phase 2 findings at AAO 2026 as Inflammasome Therapeutics prepares for a phase 3 trial.